Veru Inc VERU
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial
Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference
Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
Veru to Conduct Enobosarm Clinical Study With Novo Nordisk's Weight-Loss Pill Wegovy
Trading Information
- Previous Close Price
- $2.06
- Day Range
- $2.06–2.15
- 52-Week Range
- $2.04–7.33
- Bid/Ask
- $2.10 / $2.17
- Shares Outstanding
- 17.05M
- Market Cap
- $36.15M
- Volume/Avg
- 137,145 / 218,466
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 20
- Website
- https://www.verupharma.com
Valuation
Metric | VERU |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.27 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
VERU
Financial Strength
Metric | VERU |
|---|---|
Quick Ratio | 4.19 |
Current Ratio | 4.42 |
Interest Coverage | — |
Quick Ratio
VERU
Profitability
Metric | VERU |
|---|---|
Return on Assets (Normalized) | −65.86% |
Return on Equity (Normalized) | −90.87% |
Return on Invested Capital (Normalized) | −81.79% |
Return on Assets
VERU
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|F?W@V^T | LOCK|SJvG$ | $139B | |||
| Moderna Inc MRNA | LOCK|tV#?M%? | LOCK|S%^ | $103B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|#>^x<$ | LOCK|D$!^ | $94B | |||
| argenx SE ADR ARGX | LOCK|&C^xC^v | LOCK|Dq | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|%yd$S&& | LOCK|Rl& | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|lZNDf!Dx | LOCK|s%?& | $30B | |||
| Incyte Corp INCY | LOCK|#WXSnN^ | LOCK|L# | $24B | |||
| BioNTech SE ADR BNTX | LOCK|S$BCvgk | LOCK|X@ | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|f>h@!> | LOCK|?rnD | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|s%?#NQ | LOCK|!t^ | $15B |
United States